METROPOLIS - Metropolis Healthcare Limited Share Price

In the Q3 FY26 earnings call, management provided a positive outlook for Metropolis Healthcare Limited, highlighting strong growth potential driven by several key factors. Here are the major points:

1. Financial Performance: The group revenues grew by 26% year-on-year, with organic revenue growth at 15% for the quarter and 13% for the nine-month period. Patient volumes increased by 9%, reaching 3.3 million.

2. Margin Expansion: EBITDA margins improved to 29.3%, marking a 280 basis point increase from the previous year. Margins are expected to remain robust at around 25% for the organic business, driven by cost efficiencies and operational improvements.

3. Genomics Center: A key milestone was the launch of the Centre of Genomics in Delhi, which will enhance Metropolis' capabilities in advanced molecular testing and precision diagnostics. This area is expected to be a significant growth lever over the next few years.

4. Strategic Acquisitions: The integration of Core Diagnostics is progressing well, with expectations for improved margins in subsequent quarters. Acquisitions have enhanced Metropolis' specialty portfolio, enabling cross-selling opportunities.

5. Seasonal Outlook: Management expressed confidence in Q4, which is typically stronger for diagnostics. They anticipate achieving their guidance of 12% to 13% organic growth and gradual margin uptick for FY26.

6. Bonus Issue: The Board of Directors approved a bonus share issue of 3:1, signaling confidence in the company's financial position and long-term growth prospects.

7. Investment Plans: The estimated capex for the year is projected at INR 55-60 crores, focused on network expansion and upgrading IT systems.

In summary, Metropolis is well positioned for sustained growth, supported by robust operational performance, strategic investments in new capabilities, and an optimistic market outlook.

Questions and Answers from the Earnings Call:

1. Question: "What is the organic volume growth on the test side for this quarter?"

Answer: "Our organic test volume growth for this quarter is 8%. This demonstrates our commitment to maintaining a strong performance despite seasonal fluctuations."

2. Question: "Regarding genomic initiatives, how do you see this area contributing to future growth, given the competitive pricing landscape?"

Answer: "At Metropolis, we focus on precision-led diagnostics rather than high-volume commoditized tests. We believe genomics will increasingly play a critical role in oncology and neurology, with significant growth expected over the next decade. While competition exists, our emphasis on quality reports positions us strongly. We've been seeing rapid uptake in our genomic offerings since launch."

3. Question: "What is the thought process regarding network expansion after recent years of growth?"

Answer: "Our laboratory expansions are mainly done to service the 750 towns we're focused on. Currently, our strategy is to enhance customer service within these areas, primarily through franchise channels. We find ample opportunities for growth, especially in Tier 3 and Tier 4 cities."

4. Question: "Are there expected impacts on reagent costs due to currency fluctuations?"

Answer: "Currently, we don't anticipate any significant impacts on reagent costs. While currency fluctuations could prompt vendors to renegotiate, most of our suppliers are EU-based, minimizing risk. We remain cautious but confident."

5. Question: "Can you elaborate on the reasons behind the closure of some labs and if further closures are anticipated?"

Answer: "The closures were primarily due to duplications as we integrated recent acquisitions. We expect to continue this strategy, potentially closing a few more labs in Q4 in alignment with operational efficiency."

6. Question: "What are your expectations for sustaining patient volume growth in the future?"

Answer: "We aim for sustained volume growth around 7% to 8%. Early successes in our strategic programs solidify our belief that we can achieve this target moving forward."

7. Question: "What impact has the lower GST had on pricing, and how do you foresee pricing adjustments?"

Answer: "The GST reductions have had a marginal benefit on costs. We have delayed our usual price revision to ensure customers benefit from these reductions, but we are observing the market trends to decide on future price adjustments."

8. Question: "In terms of preventive health care testing, what has driven growth even when online players marked lower pricing?"

Answer: "Awareness and trust in our brand, along with added services like consultations, significantly contribute to our growth. While price factors in, consumers prioritize quality, trust, and comprehensive services when choosing care."

9. Question: "What is the capex guidance for the current year, and how do you see your collection center growth changing?"

Answer: "We project a capex of around INR 55-60 crores this year, focusing on improving our pan-India network and high-end equipment acquisition. We aim to gradually increase our collection centers per lab to enhance efficiency."

10. Question: "Can you provide insights on margins going forward, especially with the Labor Code impacts?"

Answer: "The recurring impact from labor charges will be around INR 5-6 crores. However, we are well-placed for sustained margin growth driven by productivity improvements, targeting about 70-100 bps expansion as indicated earlier this year."